nature portfolio

Corresponding author(s):	David Hawman and Heinz Feldmann
Last updated by author(s):	Feb 28, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
Software and code
Policy information about <u>availability of computer code</u>
Data collection N/A
Data analysis N/A
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.
Data
Policy information about <u>availability of data</u> All manuscripts must include a <u>data availability statement</u> . This statement should provide the following information, where applicable: - Accession codes, unique identifiers, or web links for publicly available datasets - A description of any restrictions on data availability - For clinical datasets or third party data, please ensure that the statement adheres to our <u>policy</u>
All data underlying the figures is available upon reasonable request.

Policy information about and sexual orientation		numan participants or human data. See also policy information about sex, gender (identity/presentation), ity and racism.
Reporting on sex and		
Reporting on race, et other socially relevar groupings		
Population character	ristics N/A	
Recruitment	N/A	
Ethics oversight	N/A	
Note that full information	on the approval c	f the study protocol must also be provided in the manuscript.
Field-speci	ific repo	orting
Please select the one b	elow that is the	best fit for your research. If you are not sure, read the appropriate sections before making your selection.
∠ Life sciences	Behav	ioural & social sciences
For a reference copy of the d	ocument with all sec	tions, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
Life science	es stud	y design
All studies must disclos	se on these poin	ts even when the disclosure is negative.
Sample size San	Sample sizes were based on our previous experience with the CCHFV NHP models	
Data exclusions No	None excluded	
Replication Exp	Experiment was not repeated due to ethical considerations of NHP work	
Randomization An	Animals were randomly assigned to study groups	
. 0	Pathologists were blinded to study groups. Due to technical constraints of the ABSL-4 environment, other research staff were not blinded to study groups	
We require information fr	rom authors about	cific materials, systems and methods some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
Matarials 9 aver-	imontal avet-	ms Methods
n/a Involved in the st		
Antibodies		
	cell lines Flow cytometry	

MRI-based neuroimaging

Palaeontology and archaeology Animals and other organisms

Dual use research of concern

Clinical data

 \boxtimes

 \boxtimes

| Plants

Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in Research</u>

Laboratory animals Macacca mulatta, age and sex for all animals are reported in supplemental tables

Wild animals N/A

Reporting on sex Sex of animals reported in supplemental tables

Field-collected samples N/A

Rocky Mountain Laboratories Animal Care and Use Committee approved all animal work

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Plants

Ethics oversight

Seed stocks

Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.

Novel plant genotypes

Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the aditor, used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor.

number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.

Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to

Authentication

assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosiacism, off-target gene editing) were examined.